Theravance Biopharma Inc (TBPH)
9.38
-0.09
(-0.95%)
USD |
NASDAQ |
May 10, 16:00
9.38
0.00 (0.00%)
After-Hours: 16:42
Theravance Biopharma Price to Book Value: 2.121 for May 10, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 2.142 |
| May 08, 2024 | 2.146 |
| May 07, 2024 | 2.157 |
| May 06, 2024 | 2.171 |
| May 03, 2024 | 2.139 |
| May 02, 2024 | 2.119 |
| May 01, 2024 | 1.999 |
| April 30, 2024 | 1.908 |
| April 29, 2024 | 2.033 |
| April 26, 2024 | 2.062 |
| April 25, 2024 | 2.067 |
| April 24, 2024 | 2.074 |
| April 23, 2024 | 2.085 |
| April 22, 2024 | 2.139 |
| April 19, 2024 | 2.112 |
| April 18, 2024 | 2.080 |
| April 17, 2024 | 2.153 |
| April 16, 2024 | 2.191 |
| April 15, 2024 | 2.243 |
| April 12, 2024 | 2.173 |
| April 11, 2024 | 2.019 |
| April 10, 2024 | 2.157 |
| April 09, 2024 | 2.144 |
| April 08, 2024 | 2.142 |
| April 05, 2024 | 2.105 |
| Date | Value |
|---|---|
| April 04, 2024 | 2.067 |
| April 03, 2024 | 2.101 |
| April 02, 2024 | 2.058 |
| April 01, 2024 | 2.042 |
| March 28, 2024 | 2.028 |
| March 27, 2024 | 2.037 |
| March 26, 2024 | 1.994 |
| March 25, 2024 | 1.981 |
| March 22, 2024 | 2.017 |
| March 21, 2024 | 2.026 |
| March 20, 2024 | 2.037 |
| March 19, 2024 | 2.001 |
| March 18, 2024 | 1.956 |
| March 15, 2024 | 1.954 |
| March 14, 2024 | 1.947 |
| March 13, 2024 | 1.99 |
| March 12, 2024 | 1.927 |
| March 11, 2024 | 1.938 |
| March 08, 2024 | 1.949 |
| March 07, 2024 | 1.965 |
| March 06, 2024 | 1.976 |
| March 05, 2024 | 1.961 |
| March 04, 2024 | 2.058 |
| March 01, 2024 | 2.135 |
| February 29, 2024 | 2.142 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.353
Minimum
Nov 02 2022
2.617
Maximum
Jan 02 2024
1.812
Average
1.828
Median
Aug 02 2023
Price to Book Value Benchmarks
| Corcept Therapeutics Inc | 5.144 |
| Nektar Therapeutics | 2.467 |
| Vanda Pharmaceuticals Inc | 0.5322 |
| Fate Therapeutics Inc | 1.100 |
| FibroGen Inc | -- |
Price to Book Value Related Metrics
| PS Ratio | 9.038 |
| Price | 9.38 |
| Earnings Yield | -10.34% |
| Market Cap | 451.78M |